In recent trading session, Biomerica, Inc. (NASDAQ:BMRA) saw 1,240,402 shares changing hands with its beta currently measuring -0.82. Company’s recent per share price level of $5.87 trading at -$1.42 or -19.51% at recent trade assigns it a market valuation of $68.87 Million. That current trading price of BMRA’s stock is at a discount of -298.47% from its 52-week high price of $23.39 and is indicating a premium of 65.08% from its 52-week low price of $2.05. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 147.82 Million shares which gives us an average trading volume of 505.98 Million if we extend that period to 3-months.
For Biomerica, Inc. (BMRA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2. Splitting up the data highlights that, out of 2 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 2 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.08 in the current quarter.
Biomerica, Inc. (NASDAQ:BMRA) trade information
In the face of being in the red today for losing -19.51%, in the last five days BMRA remained trading in the green while hitting it’s week-highest on Wednesday, Oct 14 when the stock touched $7.97-2 price level, adding 26.98% to its value on the day. Biomerica, Inc.’s shares saw a change of 92.46% in year-to-date performance and have moved -25.86% in past 5-day. Biomerica, Inc. (NASDAQ:BMRA) showed a performance of -17.33% in past 30-days. Number of shares sold short was 665.25 Million shares which calculate 1.31 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $12 to the stock, which implies a rise of 104.43% to its current value. Analysts have been projecting $11 as a low price target for the stock while placing it at a high target of $13. It follows that stock’s current price would jump +121.47% in reaching the projected high whereas dropping to the targeted low would mean a loss of 87.39% for stock’s current value.
Biomerica, Inc. (BMRA) estimates and forecasts
Statistics highlight that Biomerica, Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lessened -10.99% of value to its shares in past 6 months, showing an annual growth rate of -30.43% while that of industry is 15.5. Apart from that, the company came lowering its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to decline by -60% in the current quarter and calculating 80% increase in the next quarter. This year revenue growth is estimated to rise 62.6% from the last financial year’s standing.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $1.2 Million for the same. And 2 analysts are in estimates of company making revenue of $3.35 Million in the next quarter that will end in November 01, 2020. Company posted $1.52 Million of sales in current quarter a year earlier. Analysts are expecting this quarter sales to drop by -21.1%.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -39.3% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 11.4% while estimates for its earnings growth in next 5 years are of 0%